Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 28 November, 2000

XTL Biopharm Ltd

Stmnt re Issuance of Patent

XTL Biopharmaceuticals Limited
28 November 2000


-Patent Covers Antibodies Directed Against Hepatitis B Virus Surface Antigen-

Rehovot, Israel and New Ipswich, N.H., November 28, 2000 - XTL
Biopharmaceuticals Ltd. ('XTL') (LSE: XTL) announces that it has been issued
US Patent No. 6,146,629, (the ''629 patent') entitled, 'Human Monoclonal
Antibody Against Hepatitis B Virus Surface Antigen (HBVsAg).' This patent,
XTL's first for a specific antibody, covers human monoclonal antibodies
('MAbs') directed against the hepatitis B virus ('HBV') surface antigen
('HbsAg'). In addition, the patent covers pharmaceutical compositions for the
treatment of HBV infection containing the antibodies. These antibodies can be
given either as monotherapy or in combination with additional anti-viral

'The issuance of the '629 patent is an indication that XTL is gaining
prominence in the realm of human monoclonal antibody therapeutics to treat
infectious disease,' stated Mirit Lotan, PhD, Director of Patents and
Technology Assessment for XTL. 'XTL's therapeutic pipeline for HBV has shown
promising early trial results. This patent issuance is a positive move forward
in building our intellectual property base in monoclonal antibody therapy to
treat HBV.'

The anti-HbsAg antibodies covered by the '629 patent form part of XTL's
product XTL-001, which is undergoing clinical trials in chronic hepatitis B
infected patients. XTL-001, a combination of two high affinity human
monoclonal antibodies, is directed against two different epitopes of HbsAg and
binds to all major HBV subtypes. The antibody pair recognises different areas
of the virus as well as a wide range of viral sero types. XTL-001 was
discovered using Trimera HMAb generation technology and validated and
optimised using the Trimera model technology. Trimera is XTL's patented method
for introducing functional human tissue into mice.

XTL is developing therapeutics to treat hepatitis B, hepatitis C and other
infectious diseases using human monoclonal antibodies and synthetic chemical
products. XTL's competitive advantage lies in its proprietary Trimera
technology, which enables XTL to accelerate its internal product development
and to secure rights to drug candidates and other technology from third
parties. For more information about XTL, visit XTL's website at
XTL Biopharmaceuticals Ltd

Dr Martin Becker, Chief Executive Officer             Tel: +972 (0) 8 940 5134
Glenn Kazo, General Manager & Chief Business Officer  Tel: +1 603 878 9857

Financial Dynamics
David Yates / Sarah Mehanna                           Tel: +44 (0) 20 7269 7236